Tiny Cardiorentis Moving Acute Heart Failure Drug To End Of Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Three-year-old Swiss start-up Cardiorentis - helmed by ex-Merck Serono CEO Elmar Schnee - already has a product in Phase III and hopes its acute heart failure therapy will reach the market in 2016.